

Application Number: TRAN4-15225

From: Leonard Zon <leonard.zon@enders.tch.harvard.edu>

Sent: Monday, October 23, 2023 6:54:50 AM

To: Scott Tocher <stocher@cirm.ca.gov>; Leonard Zon <zon@enders.tch.harvard.edu>

Subject: [EXT] Irv Weissman's grant

Dear Committee,

I understand that Irv Weissman has put together a very interesting grant to test the hypothesis that using CD34+ and CD90+ selection for CD34+90+ dual positive HSC, which are cancer free and T cell free blood stem cells could lead to transformative clinical results for cancer therapy. In particular, this would allow depletion of any contaminating tumor cells from the marrow. These antibodies were created years ago, but have not been able to be evaluated clinically due to patent issues. It seems that these issues have been solved and the therapy deserves to be evaluated. I am enthusiastic about this proposal, and agree that CD34 selected cells are no substitute, as they are not cleared of either cancer cells or T cells.

Thanks

Len